LGC has sold DDS to Alliance Pharma, a portfolio company of Ampersand and KKR - Lincoln International LLC
Ampersand-backed Alliance Pharma to acquire LGC's Drug Development Solutions Business (“DDS”) and welcomes KKR as joint sh
Alliance Pharma Appoints Patrick Bennett as Chief Executive Officer | Ampersand Capital
Alliance plans Brisbane lab predicting Australian trial surge
Les 10 meilleur entreprises, cabinets et consultants en recrutement à Andrésy, Yvelines
Ampersand Capital Partners Invests in Syft Technologies | citybiz
LGC has sold DDS to Alliance Pharma, a portfolio company of Ampersand and KKR - Lincoln International LLC
Ampersand Invests in Alliance Pharma, Leading Bioanalytical CRO
Ampersand adds another CMDO to portfolio - BioProcess InsiderBioProcess International
LGC has sold DDS to Alliance Pharma, a portfolio company of Ampersand and KKR - Lincoln International LLC
News - Alliance Pharma | Ryan Klein
Resolian on Twitter: "Ampersand Invests in Alliance Pharma, Leading Bioanalytical CRO https://t.co/XKBmAYA97D" / Twitter
Branden Berns on LinkedIn: It's official. The new year has been an excellent occasion to reflect on… | 114 comments
Alliance Pharma's Acquisition of LGC's Development Solutions Business – Global Legal Chronicle
Ampersand backs Alliance and plans growth - BioProcess InsiderBioProcess International
Kugan Sathiyanandarajah on LinkedIn: Alliance Pharma + Drug Development Solutions
Alliance Pharma Appoints Patrick Bennett as Chief Executive Officer
Ampersand Portfolio Company U.S. Alliance Pharma Acquires U.K.-based LGC's Drug Development Solutions (DDS) Business | Ampersand Capital
Alliance in the News - Ampersand
À propos de nous - Nexelis, a Q² Solutions Company
LGC has sold DDS to Alliance Pharma, a portfolio company of Ampersand and KKR - Lincoln International LLC
RETOURS DES ANCIENS
Alliance Pharma Acquires LGC's Drug Development Solutions Business | citybiz
Ampersand Capital Partners på LinkedIn: U.S. Alliance Pharma Expands Early Phase Bioanalytical Services Into…
Présentation Activa Capital
